{
  "as_of": "2026-02-07",
  "clinical_trials": [
    {
      "item_id": "milvexian",
      "trial_name": "LIBREXIA AF",
      "nct_id": "NCT05757869",
      "note": "Milvexian vs apixaban in AF"
    },
    {
      "item_id": "milvexian",
      "trial_name": "LIBREXIA STROKE",
      "nct_id": "NCT05702034",
      "note": "Milvexian after ischemic stroke or high-risk TIA"
    },
    {
      "item_id": "asundexian",
      "trial_name": "OCEANIC-STROKE",
      "nct_id": "NCT05686070",
      "note": "Asundexian after non-cardioembolic stroke or high-risk TIA"
    }
  ],
  "press_releases": [
    {
      "item_id": "milvexian",
      "label": "BMS Librexia ACS update",
      "url": "https://investors.bms.com/iframes/press-releases/press-release-details/2025/Update-on-Phase-3-Librexia-ACS-Trial/default.aspx"
    },
    {
      "item_id": "asundexian",
      "label": "Bayer OCEANIC-AF stop",
      "url": "https://www.bayer.com/media/en-us/oceanic-af-study-stopped-early-due-to-lack-of-efficacy/"
    },
    {
      "item_id": "asundexian",
      "label": "Bayer OCEANIC-STROKE ISC 2026",
      "url": "https://www.bayer.com/media/en-us/bayers-asundexian-demonstrated-a-substantial-26-percent-reduction-in-stroke-after-a-non-cardioembolic-ischemic-stroke-or-high-risk-transient-ischemic-attack-with-no-increase-in-isth-major-bleeding-versus-placebo/"
    }
  ]
}
